1. Abraham S., Rivero H.G., Erlikh I.V. et al. Surgical and Nonsurgical Management of Gallstones // www.aafp.worwg/waf.pa.
2. Al-Toma A., Volta U., Auricchio R. et al. European Society for the Study of Coeliac Disease (ESsCD) guideline for coeliac disease and other gluten-related disorders // United Eur. Gastroenterol. J. 2019. Vol. 7. N. 5. Р. 583–613. DOI: 10.1177/2050640619844125.
3. Аmerican Association for the study of Liver Diseasec. https://www.aasld.org/publications/practice-guidelines.
4. Andrén-Sandberg Å. Diagnosis and Management of Gallbladder Polyps // North Am. J. Med. Sci. 2012. Vol. 4. P. 203–211.
5. Arasaradnam R.P., Brown S., Forbes A. et al. Guidelines for the investigation of chronic diarrhoea in adults: British Society of Gastroenterology // Gut. 2018. Vol. 67. P. 1380–1399. DOI: 10.1136/ gutjnl-2017-315909.
6. Azer S.A., Akhondi H. Gastritis // Treasure Island (FL): StatPearls Publishing. 2022. PMID: 31334970. https://pubmed.ncbi.nlm.nih.gov/31334970/.
7. Babai S., Auclert L., Le-Louët H. Safety data and withdrawal of hepatotoxic drugs // Therapie. 2021. Vol. 76. P. 715.
8. Bielsa-Fernández M.V., Tamayo-de la Cuesta J.L., Lizárraga-López J. et al. The Mexican consensus on the diagnosis, treatment, and prevention of NSAID-induced gastropathy and enteropathy // Revista De Gastroenterologia De Mexico. 2019. Vol. 85. Issue 2. P. 190–206.
9. Björck M., Koelemay М., Acosta S. et al. Clinical Practice Guidelines of the European Society of Vascular Surgery (ESVS) // Eur. J. Vasc. Endovasc. Surg. 2017. N. 53. P. 460e510. DOI: 10.1016/j.ejvs.2017.01.010.
10. Blaho M., Dítě P., Kunovský L., Kianička B. Autoimmune pancreatitis — An ongoing challenge // Adv. Med. Sci. 2020. Vol. 65. P. 403–408. DOI: 10.1016/j.advms.2020.07.002.
11. Bogomolov P.O. et al. Clinical study report, groups A–D. A multicentre, open-label, randomized, comparative, parallel-arm phase II study to assess efficacy and safety of Myrcludex B in combination with peginterferon alfa-2a versus peginterferon alfa-2a alone in patients with chronic viral hepatitis B with delta-agent. Final version 1.0, 11.09.2019. 141 p.
12. Bohan T.P., Helton E., McDonald I. et al. Effect of L-carnitine treatment for valproate-induced hepatotoxicity // Neurology. 2001. Vol. 56. P. 1405.
13. Brandt L.J., Feuerstadt P., Longstreth G.F., Boley S.J. ACG Clinical Guideline: Epidemiology, Risk Factors, Patterns of Presentation, Diagnosis and Management of Colon Ischemia (CI) // Am. J. Gastroenterol. 2015. Vol. 110. P. 18–44. DOI: 10.1038/ajg.2014.395.
14. Buxton I.O. Pharmacokinetics: The Dynamics of Drug Absorption, Distribution, Metabolism, and Elimination // Brunton L.L., Hilal-Dandan R., Knollmann B.C. Goodman and Gilman's: The Pharmacological Basis of Therapeutics. McGraw Hill, 2017.
15. Chalasani N., Younossi Z., Lavine J.E. et al. The Diagnosis and Management of Nonalcoholic Fatty Liver Disease: Practice Guidance From the American Association for the Study of Liver Diseases // Hepatol. 2018. Vol. 67. N. 1. P. 328–357. DOI: 10.1002/hep.29367.
16. Chang C.Y., Schiano T.D. Review article: drug hepatotoxicity // Aliment. Pharmacol. Ther. 2007. Vol. 25. P. 1135.
17. Chen M., Zhang J., Wang Y. et al. The liver toxicity knowledge base: a systems approach to a complex end point // Clin. Pharmacol. Ther. 2013. Vol. 93. P. 409.
18. Chow C.M., Leung A.K.C., Hon K.L. Acute gastroenteritis: from guidelines to real life // Clin. Exp. Gastroenter. 2010. N. 3. Р. 97–112.
19. Davis B.R., Lee-Kong S.A., Migaly J. et al. The American Society of Colon and Rectal Surgeons Clinical Practice Guidelines for the Management of Hemorrhoids // Dis. Colon. Rectum. 2018. Vol. 61. P. 284–292. DOI: 10.1097/DCR.0000000000001030.
20. Dignan F.L., Wynn R.F., Hadzic N. et al. BCSH/BSBMT guideline: diagnosis and management of veno-occlusive disease (sinusoidal obstruction syndrome) following haematopoietic stem cell transplantation // Br. J. Haematol. 2013. Vol. 163. P. 444–457. DOI: 10.1111/bjh.12558.
21. Diverticular disease: diagnosis and management NICE guideline 2019 // www.nice.org.uk/guidance/ng147.
22. EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infectionq European Association for the Study of the Liver // J. Hepatol. 2017. Vol. 67. P. j 370–398. https://easl.eu/wp-content/uploads/2018/10/HepB-English-report.pdf.
23. EASL 2021. Advances in new drugs to for curing Hepatitis B and Hepatitis D announced at ILC 2021. https://easl.eu/press-release/advances-in-new-drugs-to-for-curing-hepatitis-b-and-hepatitis-d-announced-at-ilc-2021/.
24. EASL Clinical Practice Guidelines for HFE hemochromatosis // J. Hepatol. 2010. Vol. 53. P. j 3–22.
25. EASL Clinical Practice Guidelines on the management of ascites, spontaneous bacterial peritonitis, and hepatorenal syndrome in cirrhosis // J. Hepatol. 2010. Vol. 53. P. j 397–417.
26. EASL Clinical Practice Guidelines on the prevention, diagnosis and treatment of gallstones // J. Hepatol. 2016. Vol. 65. P. j 146–181.
27. EASL Clinical Practice Guidelines: Drug-induced liver injury // J. Hepatol. 2019. Vol. 70. P. j 1222–1261.
28. EASL Clinical Practice Guidelines: Drug-induced liver injury // J. Hepatol. 2019. Vol. 70. Issue 6. P. 1222–1261. https://www.journal-of-hepatology.eu/article/S0168-8278(19)30129-1/fulltext. DOI: 10.1016/j.jhep.2019.02.014.
29. EASL Clinical Practice Guidelines: Management of alcohol-related liver disease // J. Hepatol. 2018. Vol. 53. P j 397–417.
30. EASL Clinical Practice Guidelines: Management of cholestatic liver diseases // J. Hepatol. 2009. Vol. 51. P. 237–267. DOI: 10.1016/j.jhep.2009.04.009.
31. EASL Clinical Practice Guidelines: Management of hepatitis C virus infection // J. Hepatol. 2013. J Hepatol. 2014 Feb. Vol. 60. N. 2. P. 392-420. DOI: 10.1016/j.jhep.2013.11.003.